

## PROGRAM

### Monday, April 11

8:00~8:10 **Opening remarks**

Conference Chair: Ryo Nishikawa (Japan)

8:10~9:07 **Session 1 Molecular Biology**

Moderator: Erwin Van Meir (USA)

- O-1** Genetically Engineered GBM Mouse Models: in vivo Expression of Mutated IDH1 (R132H) Gene Using the Sleeping Beauty Transposase System  
Maria G. Castro(USA)
- O-2** Pre-Clinical Efficacy of EZH2 Inhibition in the Genetically-Engineered *IDH1* Wild-Type Proneural GBM Mice  
Fumiharu Ohka(Japan)
- O-3** Mutant IDH Expression Drives Htert Reactivation as Part of the Cellular Transformation Process  
Russell Pieper(USA)
- O-4** Therapeutic Vulnerability of IDH1 Mutant Gliomas to NAD<sup>+</sup> Depletion  
Daniel P. Cahill(USA)
- O-5** Identifying Novel Vulnerabilities in Oxidative Stress Pathways in IDH1 Mutant Glioma  
Simone P. Niclou(Luxembourg)
- O-6** Mutant IDH1 Suppresses Local and Systemic Thrombosis in Glioma Patients  
Craig Horbinski(USA)
- O-7** ATRX Reduction Promotes Chemoresistance and Xenograft Growth in Glioblastoma  
Charles Eberhart(USA)
- O-8** ATRX Deficiency Promotes Invasive Behavior in Glioma Cells of Origin by Dysregulating Chromatin Accessibility and Modulating Gene Expression  
Jason T Huse(USA)
- O-9** Mitochondrial Metabolism Suppression by PGK1  
Zhimin Lu(USA)
- O-10** Alternate Activation of the Pentose Phosphate Pathway and Glycolysis Are Intrinsic to the Proliferative/Migratory Glioma Phenotype - Independent from Hypoxia  
Katrin Lamszus(Germany)
- O-11** Inhibition of Hexokinase 2 Through Tumor Glycolysis Inhibitors Identified Through a Drug Screen Inhibits Glioblastoma Growth in vitro and in vivo  
Gelareh Zadeh(Canada)
- O-12** Non-Metabolic Function of Phosphofructokinase-1 in Glioblastoma Maintenance  
Petra Hamerlik(Danmark)
- O-13** Control of Glucose Uptake in Glioblastoma Cells  
Lorenzo Magrassi(Italy)
- O-14** Glucose-Dependent Mechanism of Targeted Cancer Therapy Resistance  
Kenta Masui(Japan)
- O-15** Coexpression of Fatty Acid Synthase (FASN) and Carnitine Palmitoyltransferase 1C (CPT1C) in Human Gliomas and Glioma Stem Cell Xenografts  
Tatsuya Abe(Japan)
- O-16** SCAP Integrates Oncogenic Signaling and Metabolism for Glioblastoma Growth  
Deliang Guo(USA)

9:10~9:52

### **Session 2 Molecular Biology-2**

Moderator: Shi-Yuan Cheng (USA)

★15min (Presentation 13min + QA 2min)

- ★ O-17 Redefining the Cellular Architecture of Human Gliomas Through Large-Scale Single-Cell Analyses  
Mario L. Suva(USA)
- O-18 Drosophila Brat and Human Ortholog TRIM3 Regulate Asymmetric Cell Division in Brain Tumor Stem Cells Through Notch Signaling  
Daniel J. Brat(USA)
- O-19 Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres  
Manabu Natsumeda(Japan)
- O-20 Glioma Stemness as a Moving Therapeutic Target  
Ichiro Nakano(USA)
- O-21 Exploiting Exosomes from Human Bone Marrow Mesenchymal Stem Cells to Deliver Therapeutic microRNAs to Gliomas  
Frederick F. Lang(USA)
- O-22 Human Fat-Derived Mesenchymal Stem Cells Bioengineered to Secrete BMP4 Are Non-Oncogenic, Suppress Glioma, and Prolong Survival  
Sara Ganaha(USA)

9:52~10:15

### **Coffee Break**

10:15~11:30

### **Session 3 Molecular Biology-3**

Moderator: Ichiro Nakano (USA)

- O-23 N-Cadherin Upregulation Mediates Adaptive Radioresistance in Glioma Stem Cells  
Satoru Osuka(USA)
- O-24 Combined Targeted Inhibition of STAT3 and the Epigenetic Regulator LSD1 Sensitize Mesenchymal GBM Stem-Like Cells to Radiation  
Howard Colman(USA)
- O-25 TIE2 Mediates DNA Repair in Brain Tumor Stem Cells Via Histone Phosphorylation and ABL1 Recruiting  
Juan Fueyo(USA)
- O-26 Targeting the Tumor Microenvironment in GBM  
Karl H. Plate(Germany)
- O-27 c-Met/ $\beta$ 1 Integrin: A Receptor Complex Driving Invasive Resistance to Anti-Angiogenic Therapy  
Manish K. Aghi(USA)
- O-28 Cross-Talk of the Vascular Endothelial Growth Factor and Transforming Growth Factor-Beta Pathways in Glioblastoma  
Michael Weller(Switzerland)
- O-29 SHP-2-Upregulated ZEB1 Is Important for Pdgfralpha-Driven Glioma Epithelial-Mesenchymal Transition and Invasion  
Haizhong Feng(CHINA)
- O-30 IL-33 Orchestrates the Brain Tumor Microenvironment to Promote Glioma Progression and Therapeutic Resistance  
Donna L. Senger(Canada)
- O-31 The Role of Stress Granules in Astrocytoma Cell Signaling  
James T. Rutka(Canada)
- O-32 Tenascin C Is Developmentally Regulated by the PAX6 and DLX2 Homeobox Genes During Forebrain Development – Implications for Glioma Invasion  
David D. Eisenstat(Canada)

- O-33** NKG2D-Dependent Immune Surveillance Contributes to Anti-Tumor Effects of Chemotherapy and Radiotherapy Against Glioblastoma  
Patrick Roth(Switzerland)
- O-34** EEF1A1-PLCG1 Axis Is a Novel Therapeutic Target Against Gliomas with Acquired Temozolomide Resistance or Adaptation  
Arata Tomiyama(Japan)
- O-35** EGFR Inhibitor Resistance Mechanisms in GBM  
Joanna J. Phillips(USA)
- O-36** Up-Regulation of MSK1/ $\beta$ -Catenin Signaling Leads to Adaptive Resistance to PI3K/mTOR Inhibition in Human Glioblastoma  
W.K. Alfred Yung(USA)
- O-37** ERK Inhibitors Show Efficacy Against BRAF-Mutant Gliomas  
Theodore Nicolaides(USA)
- O-38** PID1, a Brain Tumor Growth Inhibitor, Is a Novel Interacting Partner and Regulator of Critical Receptor Kinase Signaling  
Anat Erdreich-Epstein(USA)
- O-39** Tyrosine Phosphorylation of Nuclear PTEN Promotes Therapeutic Resistance Through Enhanced DNA Damage Repair  
Frank Furnari(USA)
- O-40** HuR Multimerization Is Oncogenic in Glioma  
Louis Nabors(USA)
- O-41** Ionizing Radiation Induces BRCA1-Nuclear Export and Glioma Synthetic Lethality of PARP1 Inhibition in a P53-Dependent Manner  
Fen Xia(USA)
- O-42** A Regulatory Circuit of miR-125b/miR-20b and Wnt Signaling Controls GBM Phenotypes Through FZD6-Mediated Pathways  
Shi-Yuan Cheng(USA)
- O-43** mRNA-Seq of Tumefaction-Educated Platelets (TEPs) as a Tool for Blood-Based Diagnosis and Monitoring of Cns Lesions  
Pieter Wesseling(Netherlands)

11:33~12:15 **Session 4 Other Biological Issues**

Moderator: **Joseph Costello (USA)**

- O-44** A Glioblastoma Methylation Assay (GaMA) Developed from Genomic Analysis of Glioma Spheroid Cultures (GSCs) Predicts Response to Radiation Therapy  
Erik P. Sulman(USA)
- O-45** The Prognostic and Predictive Value of an Explant Assay of Gliomas in Response to Temozolomide  
David R. Macdonald(Canada)
- O-46** Gene-Drug Association Screening-Guided Precision Neuro-Oncology: Implication of Spatiotemporal Heterogeneity in Glioblastoma Genome  
Do-Hyun Nam(Korea)
- O-47** Precision Medicine in Recurrent Glioblastoma: A Feasibility Trial Conducted by the Ivy Foundation Early Phase Clinical Trials Consortium  
Michael D. Prados(USA)
- O-48** Personalizing the Treatment for Glioblastoma Patients  
Kerrie L. McDonald(Australia)
- O-49** Identification of Cytotoxic Chemical HUP1 Against the Temozolomide-Resistant Glioblastoma-Initiating Cells by a High-Throughput Drug Screening  
Toru Kondo(Japan)
- O-50** Biomarkers of Glioblastoma Identified by Quantitative Proteomics with Swath Mass Spectrometry  
Mitsutoshi Nakada(Japan)

- O-51**      **Molecular-Guided Neoadjuvant Chemotherapy for Gliomas**  
Hikaru Sasaki(Japan)
- O-52**      **Circulating Tumor Cells in Glioblastoma**  
Manfred Westphal(Germany)
- O-53**      **Non-Invasive Assessment of Glioblastoma Biology Using Circulating Tumor DNA**  
Colin Watts(UK)
- O-54**      **Ultra-Early Detection of Gliomas with Serum Autoantibodies for Specific Glioma Antigens**  
Yasuo Iwadata(Japan)
- O-55**      **Detection of D-2-Hydroxyglutarate in the Cerebro-Spinal Fluid of Glioma Patients with Mutant *IDH1* Genes**  
Erwin Van Meir(USA)

12:30~13:30    **Lunchtime Seminar 1**    (Sponsor: MSD K.K.)

Moderator:    **Kazuhiko Mishima (Japan)**

---

- LS-1**      **Receptor Tyrosine Kinase Signaling Underlies Tumor Growth Through Epigenome and Transcription Factor Network Remodeling**  
Webster Cavenee(USA)

13:45~15:12    **Session 5 Immunology** (Sponsor: Toray Industries, Inc.)

Moderator:    **Hideho Okada (USA)**

---

★15min (Presentation 13min + QA 2min)

- ★ **S1-1**      **Bone Marrow T Cell Sequestration with GBM**  
Peter E. Fecci(USA)
- ★ **S1-2**      **Immunological Changes During Tumor Progression from Primary to Recurrent Glioblastoma**  
Christel C. Herold-Mende(Germany)
- S1-3**      **Novel and Shared Neoantigen for Glioma T Cell Therapy Derived from Histone 3 Variant H3.3 K27M Mutation**  
Hideho Okada(USA)
- S1-4**      **Third Generation CARs with Reduced IL-2 Signaling Overcome Treg Suppression and Mount a Therapeutic Response Against Established Solid Tumors**  
Gary Archer(USA)
- S1-5**      **The CAR2Brain-Study: A Phase I Study of Local Therapy with ErbB2/Her2-Targeted NK Cells for Recurrent Glioblastoma**  
Joachim P. Steinbach(Germany)
- S1-6**      **Vaccination with Dendritic Cells Loaded with Cytomegalovirus Antigen in Patients with GBM and Associations with Overall Survival**  
John H. Sampson(USA)
- S1-7**      **Co-Stimulatory Molecules, OX40 and CD40, Augment the Efficacy of Tumor Lysate-Based Vaccines Against Malignant Gliomas**  
Ryuta Saito(Japan)
- S1-8**      **Phase I Clinical Trial of IDH1 Vaccine in Recurrent Low Grade Gliomas**  
Gordana Vlahovic(USA)
- S1-9**      **WT1 Peptide Vaccination for Glioblastomas; Survivals, Biomarkers and Response Assessments**  
Naoya Hashimoto(Japan)
- S1-10**      **Novel WT1 Peptide Vaccination for Newly Diagnosed Malignant Gliomas**  
Tetsuya Ueba(Japan)
- S1-11**      **Autologous Formalin Fixed Tumor Vaccine for Patients with Newly-Diagnosed Glioblastoma; From Concept to Double Blind Phase IIb/III trial**  
Yoshihiro Muragaki(Japan)

- S1-12** Synergistic Effects of Regulatory and Memory T Cell Modulation in Dendritic Cell-Based Immunotherapy: Impact of mTOR and NFkB Pathway  
Yohei Mineharu(Japan)
- S1-13** Therapeutical Doses of Temozolomide Inhibit IL-10 Production by Dendritic Cells and Enhance the CTL Response  
Akio Asai(Japan)
- S1-14** Engineering the Brain Immune System to Recognize and Eliminate Brain Tumors: Ad-Flt3L and Ad-TK Reconstitute Brain Immunity to Recognize Neo-Antigens –Initial Reports on a Phase I Clinical Trial  
Pedro R. Lowenstein(USA)
- S1-15** A Phase I Study of a Personalized Neoantigen Cancer Vaccine with Radiotherapy Among MGMT Unmethylated, Newly Diagnosed Glioblastoma Patients  
David Reardon(USA)
- S1-16** Glioma Microenvironment-Derived CCL2 Recruits Regulatory T Cells and Myeloid-Derived Suppressor Cells  
Maciej S. Lesniak(USA)
- S1-17** Phase I Study to Determine the MTD of a Recombinant Immunotoxin Targeting Wildtype EGFR and Mutant EGFRvIII in Recurrent Glioblastoma Patients  
Vidyalakshmi Chandramohan(USA)
- S1-18** The Effect of Ttfields on T Cells Immune Functionality  
Zvi Ram(Israel)
- S1-19** Germline Mutations Predict Response of Recurrent Glioblastoma to Immune Checkpoint Inhibition  
Uri Tabori(Canada)

15:12~15:30 *Coffee Break*

15:30~16:30 **Special Lecture** (Sponsor: Eisai Co., Ltd.)

Moderator: **Motoo Nagane (Japan)**

- SL-1** Targeting Essential Growth Drivers in Cancer  
Hiroyuki Mano(Japan)

16:45~17:48 **Session 6 Viral and Genetherapies**

Moderator: **Tomoki Todo (Japan)**

★15min (Presentation 13min + QA 2min)

- ★ **O-56** Intratumoral Administration of an Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Against Recurrent WHO Grade IV Malignant Glioma (MG)  
Annick Desjardins(USA)
- O-57** Oncolytic Poliovirus Immunotherapy of Malignant Glioma  
Matthias Gromeier(USA)
- O-58** Clinical Development of Oncolytic HSV-1 G47delta for Glioblastoma  
Tomoki Todo(Japan)
- O-59** Third Generation Oncolytic HSV-1 (G47delta) Is Efficacious Against Glioblastoma-Derived Cancer Initiating Cells  
Yasushi Ino(Japan)
- O-60** Toxicity Study of Lentiviral HSV-Tk Mediated Suicide Gene Therapy in the Rat Brain  
Hrvoje Miletic(Norway)
- O-61** Histone Deacetylase 6 Inhibition Enhances Oncolytic Viral Replication in Glioma  
E. Antonio Chiocca(USA)
- O-62** Oncolytic Viral Therapy for Brain Tumors  
Balveen Kaur(USA)

- O-63** Cell-Based Oncolytic Virotherapy of Experimental Gliomas  
Ghazaleh Tabatabai(Germany)
- O-64** Combination Viro-Immunotherapy with Checkpoint Inhibition to Treat Glioma, Based on Location-Specific Tumor Profiling  
Brian Patrick O'Neill(USA)
- O-65** Combination of Oncolytic Adenoviruses and Immune Checkpoint Targeting  
Juan Fueyo(USA)
- O-66** A Super Gene Expression System Enhances the Antitumor Effects of Adenovirus-Mediated REIC/Dkk-3 Gene Therapy  
Kazuhiko Kurozumi(Japan)
- O-67** Enhanced Efficacy of Prodrug Activator Gene Therapy with a Retroviral Replicating Vector (Toca 511) Combined with Radiation  
Masamichi Takahashi(Japan)
- O-68** Human iPSC for Cell-Based Gene Therapy of Gliomas  
Isabelle M. Germano(USA)
- O-69** Towards Clinical Development of an Autologous Stem-Cell Based Glioma Therapy Using iPSC-NSC Derivation Methods  
Nils Ole Schmidt(Germany)

17:48~18:06 **Session 7**

Moderator: Kazuhiko Mishima (Japan)

---

### Pathology

- O-70** Dual Color MGMT/CD45-HAM56 for Corrected Nuclear Counts in Glioblastoma  
Roger E. McLendon(USA)

### Other Clinical Issues

- O-71** Multi-Centre Phase I Trial of the Proteasome Inhibitor Marizomib with Bevacizumab in Patients with Progressive Glioblastoma (GBM)  
Warren P. Mason(Canada)

### Pediatric-2

- O-72** High Diagnostic Value of Placental Alkaline Phosphatase Levels (PLAP) : A New Marker for Intracranial Germ Cell Tumors  
Yasuo Aihara(Japan)

### Radiation Oncology/Imaging

- O-73** Creation of a Dual-Labeled Cancer-Targeting Alkylphosphocholine Analog for Dual Modality Quantitative PET and Intraoperative Tumor Visualization  
John S. Kuo(USA)

### Surgery, etc.

- O-74** Sonodynamic Therapy Combined with a Photosensitizer, 5-Aminolevulinic Acid for Malignant Gliomas  
Takanori Ohnishi(Japan)

Tuesday, April 12

8:00~9:09

## **Session 8 Pediatric**

Moderator: **Nada Jabado (Canada)**

★15min (Presentation 13min + QA 2min)

- ★ **O-75**     **Metastatic Dissemination of Medulloblastoma Is Through the Blood, and Is Mediated by CCL2**  
Michael D. Taylor(Canada)
- O-76**     **The Medulloblastoma Enhancer Landscape Reveals Subgroup-Specific Cellular Origins**  
Paul A. Northcott(USA)
- O-77**     **Convergence of Bmi1 and Chd7 in the Pathogenesis of Medulloblastoma**  
Silvia Marino(UK)
- O-78**     **Integrative Clustering Reveals Distinct Biological Subtypes Within Medulloblastoma Subgroups**  
Vijay Ramaswamy(Canada)
- O-79**     **BAI1 Silencing Promotes Medulloblastoma Formation Through a P53 Dependent Mechanism**  
Dan Zhu(USA)
- O-80**     **Clinical Significance of PD-L1 and CD8 Expression in Human Medulloblastoma**  
Yoshiki Arakawa(Japan)
- O-81**     **A Phase I Trial of P28, a Non-HDM2 Mediated Peptide Inhibitor of P53 Ubiquitination for Pediatric Patients Recurrent CNS Tumors**  
Stewart Goldman(USA)
- O-82**     **Disruption of GABA Metabolism in Medulloblastoma**  
Josh Neman(USA)
- O-83**     **Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma**  
Kenneth Cohen(USA)
- O-84**     **Four New Brain Tumor Entities Emerge From Molecular Classification of CNS PNETs**  
Marcel Kool(Germany)
- O-85**     **C11orf95-RELA Fusion Alone is Sufficient to Form Human Supratentorial Ependymoma-Like Tumor in Mice**  
Tatsuya Ozawa(USA)
- O-86**     **Outcome of Young Children with Supratentorial Ependymoma Treated with Radical Surgical Resection and Intensive Chemotherapy: The Head Start I-III Trials, 1991-2009**  
Jonathan L. Finlay(USA)
- O-87**     **Clinicopathological Features of Atypical Teratoid/Rhabdoid Tumor-Like Embryonal Tumors with Retained INI1 and BRG1 Expression**  
Junko R. Hirato(Japan)
- O-88**     **Heterogeneity in SWI/SNF Complex Components in Atypical Teratoid Rhabdoid Tumors**  
Alexander R. Judkins(USA)
- O-89**     **Atypical Teratoid/Rhabdoid Tumor (AT/RT) Arising from Ependymoma: A Type of Secondary AT/RT**  
Sumihito Nobusawa(Japan)
- O-90**     **Establishment of a Nationwide Molecular Diagnostic Network for Pediatric Malignant Brain Tumors in Japan**  
Yonehiro Kanemura(Japan)

9:12~10:24

### **Session 9 Pediatric-2**

Moderator: **Torsten Pietsch (Germany)**

★15min (Presentation 13min + QA 2min)

- ★ **O-91**      **Cellular Origin of Central Nervous System Germ Cell Tumors**  
Koichi Ichimura(Japan)
- O-92**      **Expression Profiling of Intracranial Germ Cell Tumors Reveals Upregulation of RAS Through mRNA-microRNA Signaling Pathway**  
Ching C. Lau(USA)
- O-93**      **Dose-Reduced Radiotherapy with Platinum-Based Chemotherapy Has Improved Quality of Life in the Long-Term Survivors with Germinoma**  
Kazuhiko Sugiyama(Japan)
- O-94**      **MicroRNA 372-373 in Cerebrospinal Fluid Is Potential Tumor-Derived Biomarkers for CNS Germ Cell Tumors**  
Keita Terashima(Japan)
- O-95**      **Long-Term Survival with Multimodal Therapy; Surgery, Carboplatin Based Chemotherapy Followed by Radiotherapy in Patients with Primary Intracranial Germ Cell Tumors**  
Kazuya Motomura(Japan)
- O-96**      **Management of Intracranial Germ Cell Tumors – International Consensus and Differences**  
Ute Bartels(Canada)
- O-97**      **Pediatric Low-Grade Glioma Molecular Stratification and Long Term Implications**  
Cynthia E. Hawkins(Canada)
- O-98**      **Type II Raf Inhibitors as Targeted Therapeutics for Pediatric Low-Grade Astrocytoma**  
Mark W. Kieran(USA)
- O-99**      **The Prognostic Factors of Pilocytic Astrocytoma in Children: A Retrospective Review of 16 Cases**  
Kentaro Chiba(Japan)
- O-100**      **Functional Diversity and Co-Operativity Between Subclonal Populations of Paediatric Glioblastoma and Diffuse Intrinsic Pontine Glioma Cells**  
Chris Jones(UK)
- O-101**      **Functional Dissection of the H3.3K27M Mutation**  
Oren Becher(USA)
- O-102**      **Histopathological WHO Grading and H3.3K27 Mutational Status Represent Independent Prognostic Markers in Pediatric High Grade Gliomas**  
Torsten Pietsch(Germany)
- O-103**      **Spatial and Temporal Homogeneity of Driver Mutations in Diffuse Intrinsic Pontine Glioma**  
Nada Jabado(Canada)
- O-104**      **Targeting Enzymatic Modifiers of Histone H3 K27 for Treating DIPG**  
Charles David James(USA)
- O-105**      **PNOC-003: Precision Medicine Trial for Children with Diffuse Intrinsic Pontine Glioma**  
Sabine Mueller(USA)
- O-106**      **Microenvironment and Tumor Cell Expansion in Diffuse Intrinsic Pontine Glioma**  
Javad Nazarian(USA)
- O-107**      **Home-Based Palliative Care for Children with Recurrent and/or Refractory Central Nervous System Tumor**  
Takaaki Yanagisawa(Japan)

10:24~10:50

**Coffee Break**



10:50~12:29 **Session 10 Molecular Genetics** (Sponsor: Nobelpharma Co., Ltd.)

Moderator: Koichi Ichimura (Japan)

★15min (Presentation 13min + QA 2min)

- ★ S2-1 **Novel Brain Tumor Subtypes Identified by Genome-Wide Methylome Profiling**  
David T.W. Jones (Germany)
- ★ S2-2 **Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma**  
Roeland GW Verhaak (USA)
- S2-3 **Genome-Wide Methylation Analysis Identifies Genomic DNA Demethylation During Malignant Progression of Gliomas**  
Akitake Mukasa (Japan)
- S2-4 **Genome and Epigenome Perspectives of Human Brain Tumor Evolution**  
Joe Costello (USA)
- S2-5 **De Novo Transcriptome Assembly Finds Novel Glioblastoma Subtype-Specific Transcripts**  
Bernhard Radlwimmer (Germany)
- S2-6 **High-Throughput Screening (HTS) of Glioma Stem-Like Cells (GSCs) Identifies Genomic Correlates of Therapeutic Response to Targeted Therapy**  
John de Groot (USA)
- S2-7 **Genomic Tests Accurately Classify Gliomas into Five Molecular Groups and Provide Additional Information on Acquired Alterations and Clinical Outcome**  
Robert B. Jenkins (USA)
- S2-8 **ATRX and TERT Assays Provide Complementary Information in Adults with IDH-Mutated Glioma**  
Kyle M. Walsh (USA)
- S2-9 **Molecular Classification Based on IDH and TERT Identified Four Clinically Distinct Subclasses: A Study of Glioma Molecular Classification Consortium**  
Hideyuki Arita (Japan)
- S2-10 **Mutations in IDH1, IDH2, and in the TERT Promoter Define Clinically Distinct Subgroups of Adult Malignant Gliomas**  
Hai Yan (USA)
- S2-11 **Preliminary Results of Phase I Study of AG-120, an Inhibitor of the IDH1 Mutant Protein, in Patients with IDH1-Mutant Solid Tumors, Including Gliomas**  
Patrick Y. Wen (USA)
- S2-12 **Detection of IDH1 Mutations in vivo by Magnetic Resonance Spectroscopy of Glutamate and 2-Hydroxyglutarate in Human Brain Gliomas**  
Kazuhiro Tanaka (Japan)
- S2-13 **NGS-Based MSK-IMPACT Analysis Reveals Specific Genetic Alterations in Recurrent Glioblastoma**  
Shinya Tanaka (Japan)
- S2-14 **Genetic Biomarkers to Predict Prognosis and Kinetics of Clonal Evolution by Mathematical Computational Modeling in Low-grade Glioma**  
Atsushi Natsume (Japan)
- S2-15 **Malignant Transformation in Oligodendroglioma with 1p19q LOH**  
Hideo Nakamura (Japan)
- S2-16 **Treatment Strategy for Grade II-III Gliomas Could Be Determined by IDH and TP53 Status**  
Yuichi Hirose (Japan)
- S2-17 **Genetic and Histological Stability of 1p/19q Co-Deleted Gliomas at Recurrence**  
Keisuke Ueki (Japan)
- S2-18 **Co-Polysomy of Chromosomes 1 and 19 Predict Early Recurrence Among Non-1p/19q-Deleted Low-Grade Gliomas**  
Rachel Grossman (USA)
- S2-19 **HDAC7 as a Possible Therapeutic Target for Mesenchymal Glioblastoma**  
Koji Yoshimoto (Japan)

- S2-20** G Protein-Coupled Receptor 158: A Potential Prognostic Biomarker in Gliomas  
Sebastian Brandner(UK)
- S2-21** Statistical Considerations for Developing Classification Models in Glioma  
Annette M. Molinaro(USA)
- S2-22** Evolution of Molecular Drivers in Glioblastomas During Temozolomide Treatment  
Tracy Batchelor(USA)
- S2-23** Intraoperative Detection of IDH1 Mutations in Diffuse Gliomas  
Takashi Komori(Japan)

12:35~12:56 **Session 11 Pathology**

Moderator: **Takashi Komori (Japan)**

---

- O-108** Detection of P53 Mutations in Proliferating Vascular Cells in Glioblastoma Multiforme  
Hideo Takeshima(Japan)
- O-109** Practical Utility of Nestin and Olig2 as Immunohistochemical Markers for Gliomas  
Hideaki Yokoo(Japan)
- O-110** Expression of Multidrug Resistant Genes in the Human Glioblastomas  
Takashi Tamiya(Japan)
- O-111** Clinical and Pathological Characteristics of Adult Diffuse Brainstem Glioma  
Shota Tanaka(Japan)
- O-112** Microtubule Networks Constitute a Major Resistance Factor in Gliomas  
Wolfgang Wick(Germany)
- O-113** Tumor-Associated Macrophages and Microvascular Proliferation in Glioblastoma  
Atsushi Sasaki(Japan)
- O-114** M2a-type Macrophages in Glioblastoma Are Characterized by Up-Regulation of ALDH1A2  
Waldemar Debinski(USA)

13:00~14:00 **Lunchtime Seminar 2** (Sponsor: Chugai Pharmaceutical Co., Ltd.)

Moderator: **Keisuke Ueki (Japan)**

---

- LS-2** The New WHO Classification of Brain Tumors  
Arie Perry(USA)

---

Wednesday, April 13

---

8:00~8:27 **Session 12 Radiation Oncology/Imaging**

Moderator: Susan Chang (USA)

---

- O-115** Magnetic Resonance Analysis of Malignant Transformation in Recurrent Glioma  
Susan M. Chang(USA)
- O-116** Magnetic Resonance Spectroscopy Detection of High Lipid Levels in Intraaxial Tumors Without Central Necrosis: A Characteristic of Malignant Lymphoma  
Kaoru Kurisu(Japan)
- O-117** Diagnostic Possibility of Positron Emission Tomography Using [18F]Fluciclovine to Diagnose and to Delineate Gliomas  
Toshihiko Wakabayashi(Japan)
- O-118** A Prospective Multicenter Single-Arm Clinical Trial of Bevacizumab for Patients with Surgically Untreatable Symptomatic Brain Radiation Necrosis  
Shin-ichi Miyatake(Japan)
- O-119** A Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab in the Treatment of Recurrent Malignant Glioma  
Jennifer L. Clarke(USA)
- O-120** Hypo-Fractionated IMRT with TMZ for GBMs -Tailor-Made Setting of Treatment Doses Owing to MGMT-Methylation Status-  
Toshihiko Iuchi(Japan)
- O-121** Gamma Knife Radiosurgery for Brain Metastases from Pulmonary Large Cell Neuroendocrine Carcinoma (LCNEC) : Report of a Japanese Multi-Institutional Co-Operative Study (JLGK 1401 Study)  
Takuya Kawabe(Japan)

8:30~9:30 **Special Seminar** (Sponsor: Southern Tohoku General Hospital)

Moderator: Yoko Nakasu (Japan)

---

- ES1-1** Proton Beam Radiotherapy for Intracranial Tumors  
Yasuhiro Kikuchi(Japan)
- ES1-2** BNCT for the Treatment of Malignant Brain Tumors in Comparison with Other Particle Radiation  
Shin-ichi Miyatake(Japan)

9:40~10:00 **Coffee Break**

10:00~10:51 **Session 13 Other Tumors**

Moderator: Kazuhiko Mishima (Japan)

---

- O-122** Genomic Characterization of Primary Central Nervous System Lymphoma  
Motoo Nagane(Japan)
- O-123** Reduced Neurotoxicity with Methotrexate-Based Multiagent Chemotherapy (M-CHOP) and Deferred Radiotherapy for Primary Central Nervous System Lymphoma  
Tomotsugu Ichikawa(Japan)
- O-124** Prognostic Impact of Completion of Initial High-Dose Methotrexate Therapy on Primary Central Nervous System Lymphoma: A Single Institution Experience  
Keishi Makino(Japan)
- O-125** PCNSL: A Single-Centre Experience of Unselected Cases Treated with MTX Monotherapy and High-Dose Chemotherapy with Autologous Stem-Cell Transplant  
Yoko Nakasu(Japan)

- O-126** Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets  
Priscilla K. Brastianos(USA)
- O-127** CD15 Is a Key Player in Non-Small Cell Lung Cancer Brain Metastasis and Is Regulated by Fut-7/4 Enzymes and Cell Cycle  
Geoffrey J. Pilkington(UK)
- O-128** Beta-Sitosterol Causes a Broad Spectrum Suppression of Melanoma Brain Metastasis  
Rolf Bjerkvig(Norway)
- O-129** NEO212: A New Drug for Triple Negative Breast Cancer Metastasis to Brain  
Thomas C. Chen(USA)
- O-130** CpG Methylation Profiling of Meningioma  
Kenneth D. Aldape(USA)
- O-131** Meningioma Tumor Volume Correlation with MIB-1 Index, Microvascular Density and Patient Outcome  
Randy L. Jensen(USA)
- O-132** <sup>177</sup>Lu-DOTATATE/<sup>90</sup>Y-DOTATOC Peptide Receptor Radionuclide Therapy in Treatment Refractory Progressive Meningioma  
Joerg C. Tonn(Germany)
- O-133** The Somatic Landscape of Schwannoma  
Sameer Agnihotri(USA)
- O-134** Web-Based Efforts to Study Brain Tumors  
Elizabeth B. Claus(USA)

10:54~11:12 **Session 14 Surgery, etc.**

Moderator: Takamitsu Fujimaki (Japan)

---

- O-135** The Use of Clinical fMRI in Brain Tumor Surgery Planning  
Joseph Megyesi(Canada)
- O-136** A Prospective Phase II Clinical Trial of 5-Aminolevulinic Acid to Correlate Intraoperative Fluorescence Intensity with Histologic Cellularity  
Mitchel S. Berger(USA)
- O-137** Early Postoperative Expansion of Parenchymal High-Intensity Areas on T<sub>2</sub>-Weighted Imaging and Delayed Cerebral Edema After Carmustine Wafer Implantation for High-Grade Glioma  
Eiichi Ishikawa(Japan)
- O-138** Safety and Efficacy of BCNU Wafers in the Treatment of Japanese Glioma Patients  
Yukihiko Sonoda(Japan)
- O-139** Efficacy and Adverse Events of Carmustine Wafers Implantation for the Treatments of High Grade Gliomas in a Single Institute  
Toshihiro Kumabe(Japan)
- O-140** Initial Experience in a Pilot Study of Blood-Brain Barrier Opening for Chemo-Drug Delivery to Brain Tumors by MR-Guided Focused Ultrasound  
James Perry(Canada)

11:15~11:39 **Session 15 Other Clinical Issues**

Moderator: Joachim Steinbach (Germany)

---

- O-141** A Complete National-Based Registration of Primary Tumours Support a Fair and Optimal Management of High International Standard  
Roger Henriksson(Sweden)
- O-142** Sex-Specific Transcriptional Networks Underlie Sex Differences in GBM Biology  
Joshua B. Rubin(USA)
- O-143** Health-Related Quality of Life in Long-Term Survivors with Grade II Gliomas: The Contribution of Disease Recurrence and Karnofsky Performance Status  
Yoshiko Okita(Japan)
- O-144** Clinicopathological Study of Long Survivors of Glioblastoma (GBM) – Multiinstitutional Retrospective Survey  
Takamitsu Fujimaki(Japan)
- O-145** Favorable Outcome of 1p/19q Co-Deleted Anaplastic Oligodendroglial Tumors Treated with PAV Chemotherapy Without Radiation Therapy  
Tomoo Matsutani(Japan)
- O-146** Phase I/II Study of a Combination of Temozolomide with ACNU for Patients with Recurrent Malignant Gliomas  
Tomokazu Aoki(Japan)
- O-147** The Importance of Early Diagnosis and Treatment in Glioblastomas  
Yoshitaka Narita(Japan)
- O-148** Molecular Subgroup Analysis of EORTC 26082 (Phase 2) Temsirolimus and RT Versus TMZ/RT->TMZ in Patients with MGMT Unmethylated Newly Diagnosed GBM  
Monika E. Hegi(Switzerland)

11:45~12:45 **Lunchtime Seminar 3** (Sponsor: Novocure Ltd.)

Moderator: Ryo Nishikawa (Japan)

---

- LS-3** Tumor Treating Fields – How to Integrate This Novel Modality in Clinical Trials for Glioblastoma  
Roger Stupp(Switzerland)

12:50~ **Closing remarks**

Conference Chair: Ryo Nishikawa (Japan) , Next Conference Chair: Rolf Bjerkvig (Norway)

---